Skip to main content

Advertisement

Table 3 Results of the meta-analysis of prognosis factors in SSc

From: Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature

  Number of cohorts HR 95% CI I2 (%) p(het) Egger’s test
Age at disease onset (per 1 year) 6 1.05 (1.04–1.07) 68.6 0.007 0.783
Age at diagnosis (per 1 year) 5 1.04 (1.04–1.05) 71.2 0.008 0.025
Male sex 21 1.87 (1.61–2.18) 50.9 0.004 < 0.001
African origin 5 1.38 (1.15–1.66) 25.0 0.255 0.774
dcSSc 23 1.90 (1.62–2.23) 58.3 < 0.001 < 0.001
Anti-Scl70 autoantibodies 13 1.38 (1.09–1.74) 49.6 0.022 0.024
ACA 8 0.62 (0.47–0.82) 56.4 0.025 0.590
Joint involvement 4 1.32 (0.82–2.12) 54.0 0.089 0.508
Renal involvement 9 2.79 (1.95–3.99) 50.9 0.039 0.512
Scleroderma renal crisis 10 3.89 (2.38–6.36) 75.6 < 0.001 0.097
ILD 14 2.34 (1.78–3.08) 69.5 < 0.001 < 0.001
Cardiac involvement 7 4.35 (2.28–8.29) 89.9 < 0.001 0.077
PH (echocardiography or RHC) 13 3.44 (2.59–4.58) 61.5 0.002 0.057
PH (RHC) 5 5.27 (2.98–9.31) 63.7 0.027 0.761
Cancer 6 2.11 (1.27–3.50) 76.2 < 0.001 0.016
  1. Results are expressed as hazard ratios with 95% confidence interval. The I2 statistics describes the percentage of variation across studies that is due to heterogeneity rather than chance. p(het) is the p value for the 2 test for heterogeneity. Egger’s test checks for funnel plot asymmetry
  2. dcSSc diffuse cutaneous systemic sclerosis, ILD interstitial lung disease, ACA anti-centromere antibodies, PH pulmonary hypertension, RHC right heart catheterization